Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
February 15, 2004Clinical Cancer Research

United States Food and Drug Administration Drug Approval Summary

View Full Paper
Ask AI
Bookmark
Share

Authors

MCMartin H. CohenRockefeller FoundationGWGrant A. WilliamsUniversity of Central ArkansasRSRajeshwari SridharaCenter for Drug Evaluation and Research

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Cohen et al. (2004) studied this question.

synapsesocial.com/papers/6a109af24fb650da4fffb86fhttps://doi.org/10.1158/1078-0432.ccr-03-0564
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1The Protein Kinase Family: Conserved Features and Deduced Phylogeny of the Catalytic Domains1988 · 5,149 citations
  2. 2The Biologic Effects of C225, A Chimeric Monoclonal Antibody to the EGFR, on Human Prostate Carcinoma1996 · 244 citations
  3. 3Evidence for epidermal growth factor (EGF)-induced intermolecular autophosphorylation of the EGF receptors in living cells.1990 · 131 citations
  4. 4RECEPTORS FOR EPIDERMAL GROWTH FACTOR AND OTHER POLYPEPTIDE MITOGENS1987 · 1,288 citations
  5. 5Type 1 growth factor receptors: an overview of recent developments1995 · 20 citations